Skip to main content

The US has probably been the most affected nations in this pandemic. And probably the fastest one to adopt the innovations around the fight against the pandemic. Owing to the situation, new partnerships are paving way for the consumers in the USA to get the same-day delivery of FDA Authorized COVID-19 test collection kits. This should help rectify the situation a bit since the early and easy detection could lead to faster tackling and in turn lesser affected individuals. But only time will tell how much the adoption and penetration rate is.

DoorDash has collaborated with Vault Health and Everlywell to deliver same-day Covid-19 PCR test collection kits to consumers across the US. The collaboration facilitates consumers’ access to two FDA- approved Covid-19 home collection kits through on-demand delivery from DoorDash’s DashMart locations. Tata Medical and Diagnostics (TataMD) and Anderson Diagnostic Labs have partnered to detect Covid-19 variants from the UK, Brazil, and South Africa with the TataMD CHECK diagnostic kit. The test kit has been approved by the Indian Council of Medical Research (ICMR), and has already conducted more than 10,000 tests. It is being looked at as an alternative to RT-PCR tests.

Monoclonal antibodies have been making headlines since Eli Lilly‘s Bamlanivimab and Regeneron‘s Casirivimab/Imdevimab received EUA to treat mild-moderate COVID-19 in November 2020. The DripAssist Supplemental Infusion Rate Monitor, a test developed by Hometa, provides a middle ground between the simplicity of gravity infusion, and the certainty of a pump to deliver these treatments. The device secures to the drip chamber of an IV set and counts drops with 99% accuracy using an infrared sensor. It operates continuously for 270 hours on a single AA battery, viable for emergency use such as a power outage or pump shortage, and in austere/pop-up medical clinics.


InnoHEALTH magazine digital team

Author InnoHEALTH magazine digital team

More posts by InnoHEALTH magazine digital team

Leave a Reply